California confirms first US case of more severe mpox strain — but risk to public remains low
Jun Li/Getty Images/STOCK
(SAN MATEO COUNTY, Calif.) — Health officials in California have confirmed the first domestic case of a more severe strain of mpox in a traveler from Eastern Africa, according to the U.S. Centers for Disease Control and Prevention.
The risk to the public remains low, according to the agency. Health officials are working to identify any people who may have been exposed to the person who recently traveled from Eastern Africa and was treated shortly after returning to the U.S. at a local medical facility, the CDC said.
Casual contact — including during travel — is unlikely to pose significant risks for transmission, the agency noted.
This is the first confirmed case in the U.S. of a strain, or clade, of the virus called clade 1b.
Another strain, clade 2b, was primarily responsible for the global outbreak in 2022. During the outbreak, mpox primarily spread through close sexual contact — and a strong vaccination effort was credited with helping slow the surge of cases. This less severe version continues to circulate in the U.S at low levels. The CDC does not currently recommend booster shots for those who are considered high-risk and already fully vaccinated.
Clade 1b was recently found in September in the Congo, likely responsible for a growing outbreak in Africa that led the World Health Organization to declare a global health emergency. Early data shows that this clade is more severe and may be spreading through other contact routes in households and often to children.
People with mpox, which was formerly known as monkeypox, often get a rash that can be located on hands, feet, chest, face, mouth or near the genitals, the CDC said.
(NEW YORK) — As two NASA astronauts gear up for a months-long unplanned stay on the International Space Station (ISS), they may also be increasing their risk of radiation exposure.
Barry “Butch” Wilmore and Sunita “Suni” Williams, who performed the first crewed test flight of Boeing’s Starliner, took off on June 5 and were only supposed to be in space for about one week.
However, several problems have arisen with the spacecraft, pushing their return to February 2025 aboard Space X’s Crew-9 Dragon spacecraft.
Space radiation is different from radiation experienced on Earth. It’s made up of three kinds of radiation: particles trapped in Earth’s magnetic field, particles from solar flares and galactic cosmic rays, NASA said.
Earth is surrounded by a system of magnetic fields, called the magnetosphere, that protects people from harmful space radiation. However, the higher a person is in altitude, the higher the dose of radiation they are exposed to.
“It’s an order of normal magnitude,” Dr. Stanton Gerson, dean of the Case Western Reserve University School of Medicine in Cleveland, told ABC News. “As you move [into] the atmosphere, you have increased radiation exposure.”
Due to prolonged exposure, astronauts can be at significant risk for radiation sickness and have a higher lifetime risk of cancer, central nervous system effects and degenerative diseases, according to NASA.
“In low earth orbit where the ISS is, astronauts are at least partially protected by the magnetosphere that protects Earth from the radiation exposure of deep space,” Dr. Rihana Bokhari, acting chief scientific officer at Baylor College of Medicine’s Translational Research Institute for Space Health, told ABC News.
“However, they do have a greater radiation exposure than those on Earth because the ISS passes through areas of trapped radiation in their orbit,” she continued. “Butch and Suni, since they are on the ISS, will not be exposed to enough radiation to seriously cause large impacts on body systems but the long duration exposure to greater radiation than on Earth could lead to an increase in the risk of cancer.”
Crews aboard the ISS receive an average of 80 mSv to 160 mSv during a six-month stay, according to a 2017 NASA report. Millisieverts (mSv) are units of measurement for how much radiation has been absorbed by the body.
Although the type of radiation is different, 1 mSv of space radiation is roughly the same as receiving three chest X-rays, the federal space agency said.
By comparison, a person on Earth receives an average of 2 mSv every year from just background radiation, NASA said.
Gerson said it’s fair to take the NASA estimates and cut them in half. This means for a three-month stay, the astronauts have a cumulative average risk of receiving 40 mSv to 80 mSv.
What’s harder to determine is the episodic risk from factors including solar flares, he said.
“There’s spike risks because there’s episodic waves of solar radiation and deep space ionic radiation that come through the magnetic field, and luckily Earth has a strong magnetic field that blocks a lot of that,” Gerson said. “If you’re on the other side of the moon, you don’t have that.”
Gerson added that NASA has done a good job of checking up on astronauts after they return to Earth as the agency and other researchers have learned more about how radiation affects the body and what signs to look for.
(SILVER SPRING, Md.) — The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years.
Cobenfy, manufactured by Bristol Myers Squibb, combines two drugs, xanomeline and trospium chloride, and is taken as a twice-daily pill. In clinical trials, this combination helped manage symptoms such as hallucinations, delusions, and disorganized thinking, which are common in schizophrenia.
“Schizophrenia is a leading cause of disability worldwide. It is a severe, chronic mental illness that is often damaging to a person’s quality of life,” Tiffany Farchione, M.D., director of the Division of Psychiatry, Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, said in the approval announcement.
“This drug takes the first new approach to schizophrenia treatment in decades,” Farchione continued. “This approval offers a new alternative to the antipsychotic medications people with schizophrenia have previously been prescribed.”
Cobenfy offers new hope for people with schizophrenia, providing an innovative treatment option that could change how this condition is managed, according to Jelena Kunovac, MD, a board-certified psychiatrist and adjunct assistant professor at the University of Nevada, Las Vegas, in the Department of Psychiatry.
“We are overdue for a medication that targets schizophrenia with a different mechanism of action,” Kunovac told ABC News.
The first drugs for schizophrenia, including chlorpromazine and haloperidol – also known by the brand names Thorazine and Haldol, respectively – were introduced in the 1950s and revolutionized treatment of the disease. However, there have been very few new medications since then, with most subsequent FDA approvals being for variations of these older drugs.
Most schizophrenia medications, broadly known as antipsychotics, work by changing dopamine levels, a brain chemical that affects mood, motivation, and thinking, Kunovac explained. Cobenfy takes a different approach by adjusting acetylcholine, another brain chemical that aids memory, learning and attention, she said.
By focusing on acetylcholine instead of dopamine, Cobenfy may reduce schizophrenia symptoms while avoiding common side effects like weight gain, drowsiness and movement disorders, clinical trials suggest. These side effects often become so severe and unpleasant that, in some studies mirroring real-world challenges, many patients stopped treatment within 18 months of starting it.
In clinical trials, only 6% of patients stopped taking Cobenfy due to side effects, noted Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb. “That’s a significant improvement over the 20-30% seen with older antipsychotic drugs,” he added.
The most common side effects of Cobenfy are nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhea, increased heart rate, dizziness and gastroesophageal reflux disease, according to the FDA announcement.
“It may prove advantageous to those who don’t tolerate what has been available,” Dr. Leslie Citrome, a clinical professor of psychiatry and expert in psychopharmacology at New York Medical College, told ABC News regarding Cobenfy. “This will provide a new approach that may work out quite nicely.”
Citrome emphasized that patients who have trouble tolerating the side effects of traditional schizophrenia medications may benefit most from Cobenfy, and that a different mechanism of action holds hope for those who have not responded adequately to existing treatments.
Schizophrenia is a mental health disorder that affects about 24 million people worldwide, or roughly one in 300 people, according to the World Health Organization (WHO). It often leads to significant challenges in daily functioning, work, and relationships, impacting both patients and their families.
The disorder typically begins in late adolescence or early adulthood and can lead to lifelong disability if not properly managed, according to the WHO, further highlighting the need for effective treatment options.
Following approval, doctors could start prescribing Cobenfy by the end of October, according to Adam Lenkowsky, executive vice president and chief commercialization officer at Bristol Myers Squibb.
Experts hope that the drug’s unique mechanism and reduced side effects will help set a new standard of care for schizophrenia patients. Studies for additional therapeutic uses, including the treatment of Alzheimer’s disease and bipolar disorder, are also underway.
Jake Goodman, MD, MBA is a psychiatry resident physician and a member of the ABC News Medical Unit.
(NEW YORK) — With the recent pick of Robert F. Kennedy Jr. to lead the Department of Health and Human Services, the environmental attorney’s views on vaccines have been thrust back into the spotlight.
Kennedy has been a prominent vaccine skeptic, arguing that more research of vaccines is needed, although he has claimed in interviews that he has “never been anti-vaccine.”
Vaccine researchers tell ABC News that his recent comments don’t align with his past campaigns and that, if confirmed, he could convince vaccine-hesitant parents to not vaccinate their children.
“He’s really not a vaccine skeptic; I’m a vaccine skeptic,” Dr. Paul Offit, director of the Vaccine Education Center, an attending physician in the division of infectious diseases at Children’s Hospital of Philadelphia and a member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee, told ABC News.
“Everybody who sits around the table at the FDA vaccine advisory committee is a vaccine skeptic, right? Show us the data, prove that this vaccine is safe, prove that it’s effective, because then and only then will we authorize it, or recommend authorization or licensure,” he said.
Offit argued that Kennedy is a “vaccine cynic,” adding, “He thinks that we’re not getting the right information, that there’s an unholy alliance between the pharmaceutical industry and the FDA with the [Centers for Disease Control and Prevention] to hide the real data, and he’s going to find the real data, which is utter nonsense.”
Claims that vaccines cause autism
Kennedy has previously claimed that the measles, mumps and rubella (MMR) vaccine — a myth that was born out of a now-debunked paper from the U.K. in 1998.
The fraudulent paper has since been discredited by health experts, retracted from the journal in which it was published, and its primary author, Andrew Wakefield, lost his medical license. More than a dozen high-quality studies have since found no evidence of a link between childhood vaccines and autism.
Dr. Peter Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, said he’s worried that COVID-19 vaccine hesitancy has spilled over into hesitancy towards childhood vaccines.
There have been more measles outbreaks this year than last year and a five-fold increase in whooping cough cases this year from the year before, according to CDC data, which Hotez says is a sign that more parents may be increasingly vaccine-hesitant.
According to the CDC, there have been a total of 277 measles cases reported in 30 states in 2024 — more than four times the amount last year — with 16 outbreaks this year compared to four outbreaks in 2023. An estimated 96% of measles cases this year were not fully vaccinated. Additionally, whooping cough cases are at the highest levels this year since 2014, according to CDC data.
This comes as vaccinations among kindergarteners dipped in the 2023-2024 school year for the fourth year in a row – failing to meet the 95% threshold goal aimed to prevent a single infection from sparking an outbreak. The last time that threshold was met was pre-pandemic, during the 2019-2020 school year.
“Now you put someone like Robert F. Kennedy Jr., the nation’s most prominent, well-known anti-vaccine activist at the top of the food chain, at the top of Health and Human Services,” Hotez said. “I don’t see how these things improve any. If anything, they could start to decline even further. …So, I worry about further erosion in the number of kids getting vaccinated in the U.S.”
Claims about the COVID-19 vaccine
Kennedy also spread vaccine misinformation during the COVID-19 pandemic including claims that Dr. Anthony Fauci, former director of the National Institute of Allergy and Infectious Diseases, and the Bill & Melinda Gates Foundation were trying to profit off a COVID-19 vaccine.
During a December 2021 Louisiana House of Representatives meeting discussing a proposal to require schoolchildren to receive the COVID-19 vaccine, Kennedy falsely called the vaccine the “deadliest vaccine ever made.”
Health officials say COVID-19 vaccines are safe and effective following clinical trials that involved tens of thousands of people, and have since helped save millions of lives.
Offit says he is worried that, as the head of the HHS, Kennedy would help select directors of the CDC, FDA and the National Institutes of Health who are not qualified, and could similarly espouse vaccine-skeptic views.
“My worry is that he is not going to pick technically competent people,” he said. “My worry is he’s going to have a role in selecting ideologues who are not well-educated about infectious diseases or vaccines, and maybe who lack government experience as well.”
Both Offit and Hotez said it will be important over the next four years for doctors to have conversations with vaccine-hesitant parents to educate them on the importance of vaccinating their children in case they are swayed by vaccine-skeptic rhetoric from Kennedy.
Offit said he is already getting emails from pediatricians about parents who are hesitant to vaccinate their children because of Kennedy’s past comments.
“Over the last few days, I’ve gotten emails from pediatricians, one particularly in Connecticut that comes to mind, where they’re saying, ‘Parents are coming in, and they’re saying they don’t want to get vaccines, in part because of what [Kennedy] said. What should we do?'” Offit said. “So, I think that’s where the rubber meets the road. It’s certainly a lot more work for clinicians than it used to be.”
